Drug Development

Listings
  • Anti-CR2 (THB-5)-Mc-VC-PABC-MMAE ADC

    Anti-CR2 (THB-5)-Mc-VC-PABC-MMAE ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a Mc-VC-PABC linker to MMAE. The MMAE is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Withi...

  • Anti-CR2 (THB-5)-Mc-MMAF ADC

    Anti-CR2 (THB-5)-Mc-MMAF ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a Mc linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ce...

  • Anti-CR2 (THB-5)-MCC-DM1 ADC

    Anti-CR2 (THB-5)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a MCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-CR2 (THB-5)-SPP-DM1 ADC

    Anti-CR2 (THB-5)-SPP-DM1 ADC

    Drug Development Shirley (New York) November 29, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (THB-5) conjugated via a SPP linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • European Life Science Innovation Congress

    European Life Science Innovation Congress

    Drug Development London (London) November 28, 2017 Check with publisher

    The European Life Science Innovation Conference 2018 will explore novel R&D and business innovation models and will serve as an effective networking platform, bringing together all the key stakeholders in the life science innovation ecosystem. Du...

  • The Value of a Human Factors Program

    The Value of a Human Factors Program

    Drug Development Fremont (California) November 27, 2017 Free

    Overview: This webinar will explain the implementation of ISO 62366 and the regulatory expectations discussed in the 2016 FDA Guidance for a compliant human factors/ usability program. Why should you Attend: This year FDA published their priority lis...

  • Act for Transportation and Logistics Professionals

    Act for Transportation and Logistics Professionals

    Drug Development Fremont (California) November 27, 2017 Free

    Overview: The FSMA is paradigm shift that moves the focus from food inspections to preventative measures and process compliance. Why should you Attend: Specific provisions of the FSMA that impacts transportation and 3rd party logistics providers Sani...

  • Anti-CR2 (clone HB135)-MCC-DM1 ADC

    Anti-CR2 (clone HB135)-MCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-CR2 monoclonal antibody (clone HB135) conjugated via a MCC linker to a DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within...

  • Anti-cKit-Maytansine ADC

    Anti-cKit-Maytansine ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody conjugated via a linker to Maytansine. The Maytansine is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...

  • Anti-cKIT (9P3)-CX1-1-DM1 ADC

    Anti-cKIT (9P3)-CX1-1-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (9P3) conjugated via a CX1-1 linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ce...

  • Anti-cKIT (9P3)-SPDB-DM4 ADC

    Anti-cKIT (9P3)-SPDB-DM4 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (9P3) conjugated via a SPDB linker to DM4. The DM4 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cel...

  • Anti-cKIT (NEG027)-SMCC-DM1 ADC

    Anti-cKIT (NEG027)-SMCC-DM1 ADC

    Drug Development Shirley (New York) November 23, 2017 1.00 Dollar US$

    This ADC product is comprised of an anti-cKIT monoclonal antibody (NEG027) conjugated via a SMCC linker to DM1. The DM1 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the ...